Orthofix April 9, 2020 Orthofix has withdrawn its 2020 guidance. For 1Q20, the company reported preliminary unaudited revenue between $104 million and $105 million, a decline of 4.7% to 3.8% compared to the prior year. While many of Orthofix's procedures have been deferred, cases for acute spine, limb preservation and trauma continue to be performed. The company has also implemented virtual tools for service support relating to its Bone Growth Therapies devices as well as virtual surgeon training for the M6-C artificial disc. Like its peers, Orthofix has instituted cost-saving measures including salary reductions. Orthofix President and Chief Executive Officer Jon Serbousek said, "We believe these temporary cost reductions and the steps we are taking to further strengthen our balance sheet will allow us to continue to execute on our strategic initiatives in the near term, and be well-positioned to provide our products to customers once elective surgery procedural volumes return to hospitals globally.